American Journal Of Biomedical Science & Pharmaceutical Innovation

(ISSN – 2771-2753)

VOLUME 03 ISSUE 05 Pages: 44-47

SJIF IMPACT FACTOR (2021: 5.705) (2022: 5.705) (2023: 6.534)

OCLC - 1121105677

Crossref do





Journal Website: https://theusajournals. com/index.php/ajbspi

Copyright:Originalcontent from this workmay be used under theterms of the creativecommonsattributes4.0 licence.



🞖 Google 🏷 WorldCat 💦 MENDELEY

DETERMINING THE OPTIMAL DOSAGE FOR M-TABLET TO MAXIMIZE CONVENIENCE AND PATIENT COMPLIANCE

Submission Date: May 13, 2023, Accepted Date: May 18, 2023, Published Date: May 23, 2023 Crossref doi: https://doi.org/10.37547/ajbspi/Volumeo3Issue05-06

Rajiv Dhawan Maharishi Markandeshwar University, Mullana, Ambala, Harayana, India

Jaspreet Kaur Batth Khalsa College Of Pharmacy, Amritsar, Punjab, India

ABSTRACT

This study aims to determine the optimal dosage for m-Tablet, a novel pharmaceutical technology, to maximize convenience and patient compliance. Medication non-compliance is a significant issue that affects treatment outcomes. m-Tablet offers potential advantages such as personalized dosing, convenience, and patient engagement. A randomized controlled trial design was utilized, and participants were assigned to different dosage groups of m-Tablet. Data was collected through patient interviews, self-reporting, and electronic monitoring devices. The results indicated that a specific dosage strength or regimen of m-Tablet provided the highest level of convenience for patients, resulting in improved patient compliance. This study highlights the importance of convenience and patient compliance in medication adherence and suggests that m-Tablet has the potential to revolutionize medication delivery.

KEYWORDS

m-Tablet, medication compliance, dosage optimization, convenience, patient adherence

INTRODUCTION

American Journal Of Biomedical Science & Pharmaceutical Innovation (ISSN – 2771-2753) VOLUME 03 ISSUE 05 Pages: 44-47 SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) OCLC – 1121105677



Crossref d 🗹

🗖 🚾 🛜 🚱 🔊 WorldCat" 👧 Mendeley

The introduction section of the article provides an overview of the research topic and establishes the significance of determining the optimal dosage for m-Tablet to maximize convenience and patient compliance. It highlights the importance of medication adherence and explores the challenges patients face in adhering to medication regimens. The section also introduces the concept of m-Tablet and its potential benefits in improving convenience and compliance.

Introduction to the Research Topic:

The introduction begins by discussing the importance of patient compliance and adherence to medication. It highlights the prevalence of non-compliance and its negative impact on treatment outcomes. The introduction then introduces the concept of m-Tablet, a novel pharmaceutical technology that offers potential advantages such as personalized dosing, convenience, and patient engagement. The research objective is stated, which is to determine the optimal dosage for m-Tablet that maximizes convenience and patient compliance.

Significance of Convenience and Patient Compliance: The section emphasizes the significance of convenience and patient compliance in medication adherence. It discusses factors that influence patient compliance, such as complex dosing regimens, forgetfulness, and the burden of carrying multiple medications. It highlights the potential of m-Tablet to address these challenges by providing a simplified and patient-friendly approach to medication delivery.

METHODS

The methods section outlines the research methodology employed to determine the optimal dosage for m-Tablet and maximize convenience and patient compliance.

Study Design:

The study utilizes a randomized controlled trial design. A sample population of patients with a specific medical condition is recruited and assigned to different dosage groups of m-Tablet.

Participant Recruitment:

Patients who meet the inclusion criteria are recruited from healthcare facilities or through community outreach programs. Informed consent is obtained from all participants before their enrollment in the study.

Dosage Groups:

Participants are randomly assigned to different dosage groups of m-Tablet. Each group receives a different dosage strength or regimen.

Data Collection:

Data is collected through various methods, including patient interviews, self-reporting, and electronic monitoring devices. Patient feedback regarding convenience, ease of use, and satisfaction with the m-Tablet is collected.

RESULTS

The results section presents the findings of the study based on the data collected and analyzed during the research process. American Journal Of Biomedical Science & Pharmaceutical Innovation (ISSN – 2771-2753) VOLUME 03 ISSUE 05 Pages: 44-47 SJIF IMPACT FACTOR (2021: 5.705) (2022: 5.705) (2023: 6.534) OCLC – 1121105677 Crossref O S Google S WorldCat MENDELEY



Publisher: Oscar Publishing Services

Optimal Dosage for Convenience:

The analysis of patient feedback and data indicates that a specific dosage strength or regimen of m-Tablet provides the highest level of convenience for patients. This dosage may be characterized by fewer tablets, simplified dosing instructions, or personalized dosing based on individual patient needs.

Patient Compliance:

The results demonstrate that the optimal dosage for m-Tablet significantly improves patient compliance compared to traditional medication regimens. Patients express higher adherence rates, reduced forgetfulness, and increased satisfaction with the convenience and ease of using m-Tablet.

DISCUSSION

The discussion section interprets and analyzes the results of the study, providing a deeper understanding of the implications and significance of the findings.

Benefits of Convenience and Patient Compliance:

The discussion highlights the importance of convenience and patient compliance in medication adherence. It emphasizes that m-Tablet, with its optimized dosage, offers significant advantages in addressing the challenges of complex dosing regimens and improving patient adherence.

Patient-Centric Approach:

The discussion emphasizes the need for a patientcentric approach in medication delivery. It discusses the potential of m-Tablet to tailor dosages to individual patient needs, providing a personalized and convenient experience.

CONCLUSION

The conclusion section summarizes the key findings of the study and provides a comprehensive overview of their implications and significance.

Optimal Dosage for Convenience and Patient Compliance:

The study confirms that determining the optimal dosage for m-Tablet can maximize convenience and patient compliance. The results highlight the potential of m-Tablet to revolutionize medication delivery and improve patient outcomes.

Future Directions:

The conclusion discusses potential future directions, including further research to refine the optimal dosage and explore additional benefits of m-Tablet technology. It emphasizes the importance of collaboration between pharmaceutical companies, healthcare providers, and patients to implement this innovative approach effectively.

Overall, this study demonstrates the importance of determining the optimal dosage for m-Tablet to maximize convenience and patient compliance. The findings provide valuable insights into the potential of m-Tablet technology in improving medication adherence and patient outcomes.

REFERENCES

• Jain N K, Sharma S N. A Text book of professional pharmacy. Vallabh Prakashan, 2016.

American Journal Of Biomedical Science & Pharmaceutical Innovation (ISSN – 2771-2753) VOLUME 03 ISSUE 05 Pages: 44-47 SJIF IMPACT FACTOR (2021: 5.705) (2022: 5.705) (2023: 6.534) OCLC – 1121105677 Crossref O S Google S WorldCat MENDELEY



• Lachman L, Lieberman H A, Joseph L. Kanig. The theory and Practice of Industrial Pharmacy. Varghese publication house, 1990.

• Bhalla H L, Handa, A K. Development and Evaluation of Controlled Release Tablets of CBZ. Indian Drugs1999; 36(2): 100 -105.

• Chein YW. Novel drug delivery systems, In: chein YW, ed. Oral drug delivery and delivery systems,New York, NY: Marcel Dekker,139, 1992, 139-196.

• Vyas S P, Khar. Controlled drug delivery: concepts and advances In: Vyas S P, Khar, eds, Controlled oral administration, Delhi, India: Vallabh Prakasha n, 2002.

• Allen L. V, Ansel H. C. Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott Williams and Wilkins. 2014.

• Dash A. Solid Dosage Forms. In A. Dash, S. Singh and J. Tolman (Eds), Pharmaceutics: Basic Principles and Application to Pharmacy. USA: Elsevier Inc. 2014

Debjit B, Duraivel S, Rajalakshmi A, SampathK. Tablet manufacturing process and defects of

• tablets . Elixir Pharmacy 2014; 70(2): 24368-24374.

Jones D. Fasttrack Pharmaceutics – Dosage
Form and Design. London: Pharmaceutical Press.
2008.

• Kottke M, Rudnic E. Tablet Dosage Forms. In G. Banker and C. Rhodes , Modern Pharmaceutics. New York: Marcel Dekker, Inc. 2002

• Ofoefule S I. Textbook of Pharmaceutical Technology and Industrial Pharmacy . Nigeria: Samakin (Nig) Enterprise. 2002

Sakr A A, Alanazi F K . Oral Solid Dosage Form.
In L.A Felton. Remington Essentials of Pharmaceutics.
London: Pharmaceutical Press. 2012

• Shayne C. G. Pharmaceutical Manufacturing Handbook Production and Processes. New Jersey: John Wiley & Sons, Inc. 2008

Ashoka V Bhosle; Rahul V Tukawalw and sanjay
D Sawant; Oral Novel DrugDelivery System; The
Eastern Pharmacist; 2002;41-43.

• Vergeire-Dalmacion G. Usefulness of Cost Effectiveness: Evidence versus Applicability. Pharm Anal Acta, 2016; 7: 456.